All articles tagged with #glp 1 medications
Chrissy Metz reveals she started using GLP-1 weight loss medications through Ro after years of skepticism, saying the treatment has improved inflammation and health lab results and quieted food noise, allowing her to focus on Broadway and her future health while hoping her openness inspires others to consider options that fit their lives.
While vacationing on a yacht with Courteney Cox and Jennifer Aniston, Amy Schumer shared updates on her weight‑loss journey, revealing that Ozempic left her bedridden with vomiting and low energy; she later switched to another GLP-1 drug (Mounjaro) and has since slimmed down, discussing her Cushing syndrome and advocating honesty about weight loss while avoiding unreal beauty standards.
Trump’s nickname for GLP-1 medications—calling them 'fat shots'—has sparked backlash from doctors and patients who say GLP-1s are life-changing for diabetes, obesity and heart health. As usage climbs nationwide and Trump seeks to lower costs, critics warn the label fuels obesity stigma and understates the drugs’ medical benefits and access barriers, including Medicaid coverage. The piece underscores the tension between political rhetoric and public health, urging focus on access and accurate understanding of obesity as a complex disease.
GLP-1 medications, used to treat diabetes, obesity and heart-related conditions, are increasingly common (about 11% of US adults, up from 3% in 2024). While many users and physicians praise their health benefits, President Trump’s labeling of GLP-1s as 'fat drugs' has drawn criticism for stigmatizing a lifesaving treatment; experts emphasize obesity’s complex causes and call for broader Medicaid coverage and policy action to improve access.
The piece surveys reported side effects of GLP-1 weight-loss drugs (like Wegovy and Mounjaro), noting that digestive issues such as nausea and diarrhea are well-documented, eye problems appear rare but possible, and pregnancy-related considerations remain uncertain. It highlights 'Ozempic face' and hair thinning as widely discussed side effects, with hair loss potentially tied to rapid weight loss and nutritional changes rather than the drugs alone. Overall, evidence varies by side effect, and more research is needed to confirm causal relationships and reversibility.
Some GLP-1 weight‑loss drugs can trigger feet that look bonier, feel painful, or no longer fit shoes after rapid weight loss. Doctors say this is usually due to thinning fat pads rather than a common drug side effect. Measures to prevent it include re-measuring feet, choosing the right shoe size, adding cushioning, and aiming for slower weight loss through adequate protein and resistance training; dose adjustments may help some patients.
Some people on Ozempic lose more than 20% of body weight, while others lose little or nothing. Dr. Puopolo explains the big factors: the strongest predictor is early weight loss in the first three months; gender, diabetes status, and emotional eating also influence outcomes. Genetic variants can blunt drug response but have small effects, and baseline GLP-1 levels are not predictive. The gut microbiome may matter, and weight loss can include lean-mass loss, making protein and resistance training important. The Wegovy pill can be as effective as the shot if taken correctly. These drugs also affect brain reward and offer cardiovascular benefits beyond weight loss; stopping them often leads to weight regain, so personalize therapy and monitor response for at least three months rather than rely on a genetic test that is still years away.
At ASCO's annual meeting, several studies suggest GLP-1 weight-loss drugs may reduce cancer risk and improve outcomes: in 110,000 women, a 30% lower incidence of breast cancer; in 27,000 breast cancer patients, a 30% lower risk of death when added to standard treatment; and in 12,000 patients with multiple cancers, a 38–50% lower likelihood of progressing to stage IV. The findings are observational and not yet definitive; more research is needed to determine whether benefits come from weight loss or direct anti-cancer effects, though anti-inflammatory and immune-modulatory mechanisms are plausible.
ACE CEO Cedric X. Bryant says older adults using GLP-1 weight-loss meds should prioritize preserving strength, physical function and lean mass through regular resistance training (2-3 days/week; six-to-ten exercises; 1-3 sets; 8-15 reps) and adequate protein (roughly 1.2-1.6 g/kg/day), with targets tailored by age and health; programming should be individualized and safety-conscious, especially for those in their 70s and beyond.
Glp-1 weight-loss meds can raise the risk of muscle and bone loss, so experts recommend a focused six-move home routine to preserve strength: goblet squat to chair, dumbbell Romanian deadlift, push-ups from the knees, seated resistance-band row, suitcase carry, and Pallof press. Perform 2–3 sets of roughly 6–12 reps for most moves (suitcase carry is about 1 minute per side). The workout can fit into a 50–60 minute weekly strength plan and should be undertaken with guidance from a physical therapist if starting fresh to ensure safe, effective practice.
GLP-1 weight-loss injections can aid short-term weight loss but may raise nutrient-deficiency risks. Most evidence linking GLP-1 use to deficiencies is observational, and there’s no proof the meds directly cause deficiencies. Address nutritional needs with a varied diet and standard vitamin/mineral supplements if needed, rather than pricey “GLP-1” products. Guidance should be personalised and involve a healthcare professional; supplements are most beneficial only when a deficiency is identified or diet cannot meet needs.
A 7-year-old Indiana girl injected about 60% of her mother’s GLP-1 diabetes medicine after misinterpreting it as stomach medicine, resulting in dehydration, vomiting, and a hospital stay. Doctors feared kidney failure, but she recovered after hospital treatment. Her mother now keeps the medication locked away to prevent a repeat incident, highlighting the importance of proper storage and supervision of prescription drugs for children.
With GLP-1 prescriptions surging for diabetes and weight loss, a 7-year-old's self-injection and hospitalization spotlight a nationwide rise in GLP-1–related poison-center calls, driven mainly by accidental dosing; experts warn of dehydration, renal risk, and even pancreatitis, urging careful dosing, secure storage, and reputable sourcing to prevent misuse and counterfeit drugs.
Trinidad-born doctors Dr. Robert Jupiter and Dr. Karen Moses return to Trinidad and Tobago to launch Stellar Medical, a stigma-free clinic focused on obesity and metabolic health. They emphasize treating obesity as a chronic, biology-driven disease, discuss GLP-1/GIP meds like Wegovy, Ozempic, Zepbound and Mounjaro, but prioritize nutrition, movement, hydration, sleep, and mental wellbeing, and will collaborate with therapists when needed.
Oprah Winfrey reflects on decades of weight struggles, describing a biologically driven “enough point” and a shift from self-blame to a science-informed approach outlined in her book Enough with Dr. Ania Jastreboff. After resisting weight-loss medications for years due to shame, she started GLP-1–type drugs about two years ago, paired with daily hiking and resistance training, and now weighs about 155 pounds—the marathon weight—and says she feels healthier and stronger at 71 than at 40. Medical experts emphasize obesity as a treatable disease, not a personal fault, and Oprah’s openness aims to reduce stigma and encourage sustainable, health-focused strategies.